Overview
Tofacitinib for the Treatment of Alopecia Areata and Its Variants
Status:
Completed
Completed
Trial end date:
2015-08-01
2015-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Stanford UniversityTreatments:
TofacitinibCriteria
Inclusion Criteria:- Age >= 18 years old
- Diagnosis of alopecia areata with >50% scalp involvement, alopecia totalis, or
alopecia universalis
- Hair loss present for at least 6 months
- No treatment for alopecia areata in past 2 months
- No evidence of hair regrowth
- Females of childbearing potential must use birth control while taking the medication
and there must be a negative pregnancy test documented prior to starting the
medication
- Fluent in spoken and written English
Exclusion Criteria:
- Age <18 years old
- Patients have received treatment known to affect alopecia areata within 2 months of
enrolling in the study
- Patients with a history of malignancy (except history of successfully treated basal
cell or squamous cell carcinoma of the skin)
- Patients known to be HIV or hepatitis B or C positive
- Patients with positive tuberculin skin test or positive QuantiFERON TB test
- Patients with leukopenia or anemia
- Patients with renal or hepatic impairment
- Patients with peptic ulcer disease
- Patients taking immunosuppressive medications, including but not limited to
prednisone, methotrexate, mycophenolate mofetil, azathioprine, tacrolimus,
cyclosporine, or TNH-alpha inhibitors
- Women of childbearing potential who are unable or unwilling to use birth control while
taking the medication
- Women who are pregnant or nursing